On May 28, Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shenuo Bio”) issued a prospectus and plans to list on the Science and Technology Innovation Board.
Established in 2008, shengnuo biotechnology main business is the research and development, production and sales of peptide APIs and preparation products.
From 2018 to 2020, Sino Bio’s revenue and net profit are both on the rise, with operating income of 270 million yuan, 320 million yuan, and 370 million yuan respectively; net profits of 29 million yuan, 48 million yuan, and 59 million yuan respectively .
In terms of product categories, Shengnuo Bio’s main income comes from preparation projects, which accounted for the highest proportion. From 2018 to 2020, the proportions were 46.92%, 58.52%, and 55.23%, and the sales amount was 120 million yuan and 1.9% respectively. 100 million yuan, 200 million yuan. The secondary income comes from raw materials, and the sales amount accounts for 19.81% to 38.02% of the year.
There are more than 40 peptide drugs on the market in my country, which mainly involve seven major fields including immunity, digestive tract, anti-tumor, orthopedics, obstetrics, diabetes and cardiovascular. Among them, immunological drugs accounted for the largest share, accounting for more than 50% of the domestic market; digestive tract and anti-tumor drugs followed, each accounting for about 20%; orthopedics, obstetrics, diabetes, and cardiovascular drugs together accounted for 7% of the total market.
From the perspective of the global peptide market, 85% of the market is concentrated in the treatment of chronic diseases such as tumors and diabetes, and emergency and surgical aids account for about 15%. In my country’s peptide market, immunity, digestive tract, obstetrics, cardiovascular (angina pectoris, myocardial infarction, etc.) are all short-term medications or emergency drugs. Oncology, orthopedics (osteoporosis treatment), diabetes and other chronic disease treatments account for only 26% of the market share. %, there is more room for improvement.
Betotocin preparations and atosiban acetate preparations are important products of Shengnuo Biotechnology.
According to data from Meinenet, the domestic market for carbetocin preparations in 2019 was 173 million yuan, with a compound growth rate of 16% from 2015 to 2019, showing an overall growth trend; the domestic market for atosiban preparations was 195 million yuan, The compound growth rate from 2015 to 2019 is 71%, which is a relatively fast growth rate. In 2019, the domestic market share of Carbetocin preparations from Sino Biotech reached 20.97%, ranking second; the market share of atosiban acetate preparations was 2.82%, ranking third.
At present, the main customers of Shengnuo Biotechnology are China National Pharmaceutical Group Co., Ltd., Shanghai Pharmaceutical Group Co., Ltd., and major public and private hospitals. In 2020, the company cooperated with 256 third-level public hospitals, accounting for 22.18%; second-level public hospitals reached 668, accounting for 57.89%; first-level public hospitals reached 89, accounting for 7.71%; private hospitals reached 130, Accounted for 11.27%.